Wonderful remarks from @US_FDA Chief Counsel Mark Raza, with insightful and entertaining reflections from his 30+ year career with the Office of Chief Counsel. Thanks so much for joining us this morning.
#FDLIAnnual23#FDLI_TAKEOVER
Congress is considering inflation-based rebate penalties in #Medicare to address high brand-name drug costs. AAM SVP @ErikCKomendant shares why this proposal could hurt competition & threaten #patientaccess to affordable #generic & #biosimilar medicines. https://t.co/KZuTXP85OO